ACCOUNTS - Final Accounts preparation

ACCOUNTS - Final Accounts preparation


Caseware UK (AP4) 2019.0.131 2019.0.131 2019-12-312019-12-31true2018-09-13truefalseNo description of principal activity1The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 11566711 2018-09-12 11566711 2018-09-13 2019-12-31 11566711 2018-01-01 2018-09-12 11566711 2019-12-31 11566711 c:Director1 2018-09-13 2019-12-31 11566711 d:FurnitureFittings 2018-09-13 2019-12-31 11566711 d:FurnitureFittings 2019-12-31 11566711 d:FurnitureFittings d:OwnedOrFreeholdAssets 2018-09-13 2019-12-31 11566711 d:ComputerEquipment 2018-09-13 2019-12-31 11566711 d:ComputerEquipment 2019-12-31 11566711 d:ComputerEquipment d:OwnedOrFreeholdAssets 2018-09-13 2019-12-31 11566711 d:OwnedOrFreeholdAssets 2018-09-13 2019-12-31 11566711 d:CurrentFinancialInstruments 2019-12-31 11566711 d:CurrentFinancialInstruments d:WithinOneYear 2019-12-31 11566711 d:ShareCapital 2019-12-31 11566711 d:RetainedEarningsAccumulatedLosses 2019-12-31 11566711 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2019-12-31 11566711 c:FRS102 2018-09-13 2019-12-31 11566711 c:AuditExempt-NoAccountantsReport 2018-09-13 2019-12-31 11566711 c:FullAccounts 2018-09-13 2019-12-31 11566711 c:PrivateLimitedCompanyLtd 2018-09-13 2019-12-31 11566711 d:AcceleratedTaxDepreciationDeferredTax 2019-12-31 11566711 2 2018-09-13 2019-12-31 iso4217:GBP xbrli:pure

Registered number: 11566711









PHARMAZON LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 DECEMBER 2019

 
PHARMAZON LIMITED
REGISTERED NUMBER: 11566711

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2019

2019
Note
£

Fixed assets
  

Tangible assets
 4 
6,379

  
6,379

Current assets
  

Stocks
  
128,000

Debtors: amounts falling due within one year
 5 
126,447

Cash at bank and in hand
 6 
48,408

  
302,855

Creditors: amounts falling due within one year
 7 
(192,856)

Net current assets
  
 
 
109,999

Total assets less current liabilities
  
116,378

Provisions for liabilities
  

Deferred tax
 9 
(1,212)

  
 
 
(1,212)

Net assets
  
115,166


Capital and reserves
  

Called up share capital 
  
50,000

Profit and loss account
  
65,166

  
115,166


Page 1

 
PHARMAZON LIMITED
REGISTERED NUMBER: 11566711
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2019

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 12 June 2020.




................................................
S T Hundal
Director

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
PHARMAZON LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2019

1.


General information

The legal form of the entity is a private company limited by share capital.  The company is registered in England and Wales and the trading address is situated at 9 Lancaster Court ,Coronation Road, Cressex Business Park, High Wycombe, Buckinghamshire HP12 3TD. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 3

 
PHARMAZON LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2019

2.Accounting policies (continued)

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Current and deferred taxation

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of Financial Position date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures and fittings
-
20%
Computer equipment
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 4

 
PHARMAZON LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2019

2.Accounting policies (continued)

 
2.7

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first outbasis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.8

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.11

Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to profit or loss in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Statement of Financial Position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Statement of Financial Position.

 
2.12

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially
Page 5

 
PHARMAZON LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2019

2.Accounting policies (continued)


2.12
Financial instruments (continued)

and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in the case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Investments in non-convertible preference shares and in non-puttable ordinary and preference shares are measured:
at fair value with changes recognised in the Statement of Comprehensive Income if the shares are publicly traded or their fair value can otherwise be measured reliably;
at cost less impairment for all other investments.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the reporting date.

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or income as appropriate. The company does not currently apply hedge accounting for interest rate and foreign exchange derivatives.


3.


Employees

The average monthly number of employees, including directors, during the period was 1.

Page 6

 
PHARMAZON LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2019

4.


Tangible fixed assets





Fixtures and fittings
Computer equipment
Total

£
£
£



Cost or valuation


Additions
3,041
4,772
7,813



At 31 December 2019

3,041
4,772
7,813



Depreciation


Charge for the period on owned assets
370
1,064
1,434



At 31 December 2019

370
1,064
1,434



Net book value



At 31 December 2019
2,671
3,708
6,379


5.


Debtors

2019
£


Trade debtors
13,061

Other debtors
113,386

126,447



6.


Cash and cash equivalents

2019
£

Cash at bank and in hand
48,408

48,408


Page 7

 
PHARMAZON LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2019

7.


Creditors: Amounts falling due within one year

2019
£

Trade creditors
38,302

Corporation tax
14,143

Other creditors
138,261

Accruals and deferred income
2,150

192,856



8.


Financial instruments

2019
£

Financial assets


Financial assets measured at fair value through profit or loss
48,408




9.


Deferred taxation



2019


£






Charged to profit or loss
(1,212)



At end of year
(1,212)

The deferred taxation balance is made up as follows:

2019
£


Accelerated capital allowances
(1,212)

(1,212)

Page 8

 
PHARMAZON LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2019

10.


Transactions with directors

The director has provided interest free loans to the company that is repayable on demand. The amount outstanding as at the balance sheet date to the director is £135,850 and is included in creditors amounts falling due within one year.


11.


Related party transactions

Included in debtors are amounts of £74,889 due to entities controlled by the director. The amounts outstanding are repayable on demand and free of interests.

 
Page 9